Posted by Michael Wonder on 15 Jun 2026
Belite Bio completes rolling submission of new drug application to US FDA for tinlarebant for the treatment of Stargardt disease type 1
12 June 2026 - Belite Bio today announced the completion of its rolling submission of a new drug application to the US FDA for tinlarebant.
Tinlarebant is an investigational, once daily oral therapy for the treatment of Stargardt disease type 1, a rare, inherited retinal disease caused by mutations in the ABCA4 gene that leads to progressive and irreversible vision loss.
